ArchiveJuly 2013

Progressive MS trials

Koch MW, Cutter G, Stys PK, Yong VW, Metz LM. Treatment trials in progressive MS-current challenges and future directions. Nat Rev Neurol. 2013 Jul 30. doi: 10.1038/nrneurol.2013 The introduction of immunomodulatory treatments has transformed the management of patients with relapsing-remitting multiple sclerosis (MS), but has had no consistent benefit in progressive MS. Patients with primary or...

Phase IV Tysabri data

#MS Research # MSBlog Effect of Tysabri Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B...

First case of PML that may be attributable to fingolimod

#MS Research # MSBlog PML after Gilenya Reuters: Patient taking Novartis MS pill developed rare disease. Tue Jul 30, 2013 2:48pm IST … A patient taking Novartis’ multiple sclerosis pill Gilenya developed a rare and potentially fatal viral disease, the Swiss drugmaker said on Tuesday, an unexpected setback as it faces growing competition from new oral treatments…. …...

Too much brain Iron may be bad for the nerves

Hametner S, Wimmer I, Haider L, Pfeifenbring S, Brück W, Lassmann H. Iron and neurodegeneration in the multiple sclerosis brain.Ann Neurol. 2013 Jul 19. doi: 10.1002/ana.23974. [Epub ahead of print]Objective: Iron (pronounced eye-urn) may contribute to the pathogenesis and progression of multiple sclerosis (MS) due to its accumulation in the human brain with age. Our study focused on non-heme...

Vitamin E analogue has remyelinating potential

Tocopherol Derivative TFA-12 Promotes Myelin Repair in Experimental Models of Multiple Sclerosis. Blanchard B, Heurtaux T, Garcia C, Moll NM, Caillava C, Grandbarbe L, Klosptein A, Kerninon C, Frah M, Coowar D, Baron-Van Evercooren A, Morga E, Heuschling P, Nait Oumesmar B. J Neurosci. 2013 ;33:11633-11642. Multiple sclerosis (MS) is an inflammatory disease of the CNS that is associated with...

Mitoxantrone

Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in WorseningMultiple Sclerosis) study. BMC Neurol. 2013;13(1):80. [Epub ahead of print] BACKGROUND:Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis (RENEW) was a 5-year, phase IV study in which the safety of Mitoxantrone...

Aubagio affects relapsing MS without stopping vaccination to Flu

Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, Truffinet P, Benamor M, Chambers S, O’Connor PW.Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013 Jul  [Epub ahead of print] OBJECTIVE: To investigate the effect of teriflunomide on the efficacy and safety of seasonal influenza vaccine. METHODS:...

Radiologically Isolated Syndrome..Real or a Red Herring

Gabelic T, Ramasamy DP, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Hojnacki D, Ramanathan M, Zivadinov R. Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Multiple Sclerosis Patients.AJNR Am J Neuroradiol. 2013 Jul 25. [Epub ahead of print]BACKGROUND AND PURPOSE:The exact prevalence of WM signal abnormalities in healthy...

Thiamine for Fatigue

Costantini A, Nappo A, Pala MI, Zappone A High dose thiamine improves fatigue in multiple sclerosis. BMJ Case Rep. 2013 Jul 16;2013. The majority of the patients with multiple sclerosis (MS) experience fatigue. Some observations indicate that fatigue and related manifestations concomitant with MS could be associated with an intracellular mild thiamine deficiency. We recruited 15 patients with MS...

Rituximab review

Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One. 2013 Jul 2;8(7):e66308 BACKGROUND:Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS.OBJECTIVES:To evaluate the efficacy and safety of...

Translate

Categories

Recent Posts

Recent Comments

Archives